Member Info for rivaldo

Even more excellent news today....has to be the likes of Superdry, and should prove extremely remunerative once rolled out:

Https://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-COVID-19-testing-agree/84059341

"COVID-19 testing agreement with UK high street retail and pharmacy group

SourceBio International plc (AIM: SBI), an international provider of integrated state of the art laboratory services and products, announces that it has entered into a supply agreement with a leading UK high street retail and pharmacy group to provide laboratory-based testing services to support the roll-out of COVID-19 testing across UK stores.

Under the initial 12-month agreement SourceBio will offer COVID-19 PCR Testing services from its ISO 15189 accredited laboratory facility in Nottingham. The service is being trialled initially across a limited number of clinically approved high street sites with the goal to offer larger-scale COVID-19 diagnostic testing across many more UK stores should it prove successful.

SourceBio currently provides COVID-19 testing services to the NHS, the Department of Health & Social Care and private healthcare customers. The Company admitted to trading on AIM in October 2020 and raised funds to expand testing capacity to meet the expected increase in demand for COVID-19 testing services from additional commercial customers.

etc"

FYI, a new review by Mark Watson-Williams on Master Investor, concluding thus:

Https://masterinvestor.co.uk/equities/surface-transforms-revs-up/?mc_cid=3719b23cf9&mc_eid=db9f9bbaf2

"The company’s shares, which are trading at around 50p, just a few pence short of their all-time High of 56.5p, could easily rise to over 65p, thereby valuing it at £100m.

This is serious money for a serious technology that has masses of profit-earning potential – there are loads of stocks out there with far higher valuations for less enticing prospects."

More good news for SBI - on Friday Oxford Nanopore won a £4m LamPORE Mobile Laboratories contract from the Depatment of Health, for Mobile Laboratories fitted out with LamPORE equipment to further enable mass testing.

This "will reduce transit time for samples to travel to a static lab location therefore reducing test turnaround time".

Https://bidstats.uk/tenders/2021/W01/742523231

Per last month's agreement, the LamPORE tests are being sent to SBI for assessment "at SourceBio's state-of-the-art ISO15189 accredited laboratory facility in Nottingham to offer a large-scale COVID-19 diagnostic testing service".

Https://www.prnewswire.co.uk/news-releases/oxford-nanopore-and-sourcebio-announce-commercial-partnership-for-uk-covid-19-testing-service-873764622.html

Damian Cannon is a well-followed PI who has recently posted his 2020 portfolio review - in it he has a useful synopsis of FNX as follows:

"Fonix Mobile Bought at 126p - December 20

This is a very new addition to the stock market, listing in October. Ordinarily I steer clear of companies with a short public history but this piece by Martin Flitton piqued my interest due to the overlap in some of our holdings. Looking at Stockopedia, growth over the last few years has been very strong with profits rising 158% on an almost doubling of revenue. Margins are high, and rising, while the ROCE and FCF conversion numbers are both very high due to the capital-light business model.

In a nutshell Fonix is a mobile payments and messaging platform provider that allows consumers to make payments with their mobile phone. Fonix takes a commission from the end merchant and pays on a commission to the mobile operator; it's the difference between these two numbers that drives profits. Currently Fonix is UK focused with much of its revenue coming from the gaming and charity sectors. Future growth will come from taking carrier billing into new verticals and expanding internationally.

So far management don't appear to have put a foot wrong although I do need to go through the admission document to make sure that there's nothing nasty lurking in the fine print. If the prospectus is clean then analyst forecasts for 12% EPS growth in 2021 and 2022 look very undemanding (a point made in the Momentum Investor newsletter recently). I suspect that the broker is being cautious while there's so little information available which is why I've taken an initial position."

£4k of buys today has pushed the bid price up 4p :o))

That £4.1m and rising cash pile (40% of the m/cap) must be burning a hole in the directors' pockets given the stated intention to make acquisitions.

They said in October the new financial year had started well - the current lockdown won't help, but hopefully it will be relatively short, and CSSG's trading was "resilient" through the first lockdown as evidenced by the final results.

That link to the interview doesn't seem to be accepted here - let's try this one:

https://vimeo.com/497571882

PIworld, thanks for posting the presentation below - it really helped me a lot in explaining what RAI actually do and their recent transformation.

Here's an interview with the analyst from Zeus following the trading update - there's really only Brembo and SCE in a multi-billion market:

https://www.***************************/surface-transforms-the-disrupter-in-a-market-of-billions-analyst-interview/412951652

CNIC are in both of Techinvest's and SCSW's ongoing portfolios.

Hopefully it'll be in one or both of their nap tips for 2021, along with a few others in my portfolio!

CNIC just needs a little push to establish new 7-year highs - once that happens it's blue sky upwards.

Yep, today's RNS shows the Sukari expansion is progressing nicely - and quickly, ready for "the commencement of preliminary mining activity in late Q1 as planned".

Hopefully this will be followed by the usual January trading update in the next few days outlining continuing positive trading as per the bullish Q3 update:

Https://www.londonstockexchange.com/news-article/CAPD/sukari-contract-financing-update/14819084

Off we go....buying coming in at 283p-285p now.

Good to see the bid price back up to 95p.

News via a trading update or the first of the three mooted acquisitions could come at any time.

SBI are offering home testing COVID-19 tests FYI, i.e Government approved 'Test to Release' Covid-19 Antigen RT-PCR tests .

You can reduce your self isolation time when arriving back from your holiday or business trip. Order online - only a 24 hour turnaround time:

Https://coviduk.sourcebioscience.com/?utm_source=linkedin&utm_medium=_&utm_term=source+bioscience&utm_content=e5c5bc23-d4bf-4dd8-92b0-50cd9e625cdb&utm_campaign=default+post

Following the Chairman's sizeable buy, a divisional CEO has just bought another £10,000 of shares at just over 19.3p each.

Multiple director buying at increasing prices is always good to see :

https://www.investegate.co.uk/carclo-plc--car-/rns/director-pdmr-shareholding/202101071135039451K/

He's been buying and has increased his stake to 4.22%, or 3.13m shares.

He has quite the following in the City, so we may be in for more good times ahead:

Https://www.investegate.co.uk/sourcebio-intl-plc--sbi-/rns/holding-s--in-company/202101071031599200K/

Here's the video of last night's CNBC comment, which partly explains GAN's rise yesterday as well as the excellent news from New York - great to see GAN picked out from all the rest:

Https://www.cnbc.com/video/2021/01/06/gaming-stocks-jump-as-new-yorks-cuomo-proposes-online-betting-legalization.html

Encouraging results this morning from CAPD's drilling for ALT.

Most importantly, there's confirmation today that after the current drilling campaign completes, there are a number of additional prospects which will be drilled in a follow-up drilling programme:

Https://www.investegate.co.uk/altus-strategies-plc--als-/rns/high-grade-gold-intercepts-at-diba--mali-drilling/202101070700048453K/

Cheers MrMack, much appreciated.

Nice start again this morning, up another 2.5% already....

JDG reported this morning they traded ahead of expectations for 2020. That puts them on a historic P/E of around 42 given the 151.8p EPS consensus stated in their RNS.

For SDI's year ending 30th April an equivalent P/E would put SDI at a 190p share price.

Certainly something to aim for!

From Finncap this morning - extracts:

"Forecasts and valuation. We are not making any changes to forecasts at the moment and reiterate our SOTP target price of 310p, which assumes a rNPV valuation for pre|CISION of c.55p. We have a high/low valuation of 796p and 211p, respectively, which reflects different assumptions for its SARS-CoV-2 antigen tests."

"Avacta announced a license agreement with POINT Biopharma to use its pre|CISIONâ„¢platform for generating tumour-activated radiopharmaceuticals. This represents (i) a first deal for the pre|CISION platform despite not yet having entered the clinic (AVA6000 expected in Q2 2021) in (ii) an area outside Avacta's core focus of targeted chemotherapies that is (iii) non-exclusive after the first product developed by POINT, with the potential to create incremental value for shareholders. We reiterate our SOTP target price of 310p, which assumes an rNPV valuation for Avacta's first two pre|CISION chemotherapies of c.55p. This should rise substantially on positive data from either Avacta in H2 2021 or POINT."